The benefit of treatment has outweighed the clinical impact of lipodystrophy, conference hears
Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk
Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate
Efavirenz appears to be associated with elevated suicide risk in START trial
Switching from tenofovir DF to TAF improves bone and kidney safety
Rare but severe liver side-effects reported among South African patients starting efavirenz-based ART
In Option B+, side-effects and needing time to think are key reasons for not taking HIV medication
START study shows that people starting HIV treatment earlier have better quality of life
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity
